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ABSTRACT 
 The anatomy of the head and neck is closely associated with the nervous 
system which plays an important role in the prognosis of head and neck cancer 
(HNC). However, the molecular interactions between these compartments and 
HNC remain poorly understood.  We present a novel big data approach utilizing 
clinical data, sequencing, and machine learning to identify and validate potential 
molecular pathways by which the nervous system affects the development and 
progression of HNC.  Our studies demonstrate across multiple datasets that 
perineural invasion (PNI) frequently occurs in HPV+ HNC.  Furthermore, we 
show novel activating and missense mutations and pathways that may play 
important roles in the progression of HNC.  We hypothesized that HPV+ cancers 
might be driven by different neurotrophic-associated genes and programs.  We 
observed that neuroendocrine and neurotrophin signaling through the nerve 
growth factor receptor (NGFR) can be observed in differentiating HPV+ versus 
HPV- and PNI+ versus PNI- HNC.  These observations may provide significant 
therapeutic targets for HNC.
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 CHAPTER 1 
INTRODUCTION 
 
The Head and Neck anatomy includes intricately interconnected 
neurologic, immunologic, and endocrine tissues.  As the terminus of the 
aerodigestive tract, this region is also continually exposed to pathogens. As a 
result, many chronic diseases of the head and neck - including neoplasia - 
pathologically involve diverse neurological, endocrine, and immunological 
components.  Despite seminal historical discoveries suggesting these 
relationships, diagnostic and scientific understanding of the molecular 
underpinnings and drivers of head and neck neoplasia remain poorly understood. 
Head and neck cancers (HNC) constitute approximately 3% of all new 
cancer diagnoses per year (Leemans et al. 2011). HNC risk factors include 
stress-related behaviors such as tobacco use and alcohol abuse, and infection 
with oncogenic viruses like human papilloma virus (HPV), Merkel Cell 
Polyomavirus (MCPyV), and Epstein-Barr Virus (EBV) (Kang et al. 2016).  Thus 
a mosaic of drivers exist in HNC.  Despite the discovery of interactions between 
HNC and the nervous system through early anatomical studies of perineural 
invasion (PNI) in HNC, accurate pathologic diagnosis and staging of PNI remains 
a confounding factor in management of the disease (Cruveilhier 1835).  It is 
estimated that PNI is present but misdiagnosed in up to 70% of cases and that
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involvement with nervous tissues occurs between 40-95% of all patients with 
HNC (Chi et al. 2016; Johnston et al. 2012).  The anatomical involvement of 
neuroendocrine and the nervous system structures has recently become an area 
of translational inquiry.  
Interactions between these tissues and the presence of PNI in diseases of 
the head and neck offer compelling potential to better understand HNC.  To this 
end, we hypothesize that unique neural, endocrine, and immunological pathways 
are present in HNC.  Our projects explore the molecular relationships between 
PNI, neuroendocrine tissues, oncogenic viruses and outcomes in HNC. 
Through the use of machine learning and big data analytic techniques conducted 
in clinical HNC samples, we have successfully identified molecular targets 
including those involved with the peripheral nervous system and neurotrophic 
factor signaling.  We have deployed clinical trial evaluation in retrospective and 
prospective trials to better elucidate the importance of this triad of neurological, 
endocrine, and immunologic interactions.  Taken together, these big data 
findings provide compelling translational targets and potential strategies for the 
palliation and treatment of HNC. 
REFERENCES 
Chi AC, Katabi N, Chen H-S, Cheng Y-S L.  Interobserver variation among 
pathologists in evaluating perineural invasion for Oral Squamous Cell 
Carcinoma. Head Neck Pathol. 2016, 10(4): 451-464. 
 
Cruveilhier J. Maladies des nerfs. In: Cruveilhier J, ed. Anatomie Pathologique du 
Corps Humain. 2nd ed. Paris, France: JB Bailliere. 1835:1-3. 
 
Kang H, Kiess A, Chung CH.  J. Emerging biomarkers in head and neck cancers 
in the era of genomics. Nature Reviews Clinical Oncol. 2016, 12: 11-2
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CHAPTER 2 
MACHINE LEARNING AND MOLECULAR PATHWAY ANALYSIS OF PNI IN 
HNC 
Perineural invasion (PNI) in cancers of the head and neck (HNC) is 
universally associated with poor progression-free survival and decreased 
mortality (Johnston, Yu, and Kim, 2012).  Patients present with increased 
locoregional recurrence, metastasis, and treatment failure.  Despite the clear 
association with a more severe clinical picture, and historic observation of this 
aggressive sub-type of HNC, diagnosis and treatment remain technically limited 
with few validated markers of perineural involvement (Soo et al., 1986; 
Brandwein-Gensler et al., 2005; Vural et al., 2000; Carter et al., 1983). 
Pathologic diagnosis of perineural involvement is often only revealed by serial 
sectioning by experienced pathologists and is often an incidental finding 
(Brandwein-Gensler et al., 2005; Fagan et al., 1998; Kurtz et al., 2005).  Early 
recurrence also drives a more extensive work-up and often indicates repeated 
cycles of chemoirradiation.  Current standard of care recommends salvage 
intensity modulated radiotherapy and RTOG trials investigating adjuvant 
cetuximab are underway, however these studies are not designed specifically to 
address PNI (Johnston, Yu, and Kim, 2012).  Control rates of post-operative 
elective intensity modulated radiation therapy (IMRT) versus patients who were 
not treated with IMRT were recently reported at 100% and 82%, respectively 
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(Kropp et al., 2013). Despite long-term appreciation of this clinical entity the 
molecular underpinnings differentiating neurotrophic cancers in the head and 
neck from non-neurologically invasive disease remain poorly understood.  Soo 
and colleagues demonstrated early treatment failure, diminished three-year 
survival and increased locoregional recurrence in perineural disease (Soo et al., 
1986).   Several other retrospective studies have evaluated the proximity of 
lesions to nerves < 1mm in diameter demonstrating the importance of this metric 
in the pathologic work-up of these tumors (Brandwein-Gensler et al., 2005; 
Fagan et al., 1998).   
To better assess molecular drivers of PNI we retrospectively analyzed the 
recently published The Cancer Genome Atlas (TCGA) pan-cancer dataset for 
clinical, molecular, and survival trends significant in pathologically diagnosed PNI 
versus non-neurotrophic HNC (Kandoth et al., 2013). TCGA is a National Cancer 
Institute supported genomic consortium designed to enhance community and 
clinical knowledge of genomic drivers for the most malignant cancers. 
We herein confirm previous reports of a diminished overall survival in 
patients with PNI+ HNC and this is correlated with commonly described 
mutations in HNC in both PNI+ and PNI- disease.  Lesions with PNI also 
occurred more frequently within the oral tongue and appeared to be driven by 
neurogenic pathways while PNI- lesions were significantly associated with 
alterations of SMAD2/4 signaling.  Importantly, this analysis revealed several 
significantly up-regulated pathways related to neurogenesis and neural signaling 
that have yet to be described in HNC.  Taken together, these neurogenic-related 
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targets provide a rational explanation for the decreased survival and aggressive 
disease in PNI+ HNC, and suggest alternative mechanisms which may be 
exploited to benefit patients with aggressive disease. 
2.1 MATERIALS AND METHODS  
Data Source 
The TCGA is an initiative to provide publicly available sequencing, 
mutational, and expression data for 25 selected cancers to generate advances in 
clinical discovery. These studies were exempt from formal review by the 
University of South Carolina Institutional Review Board and complied with the 
TCGA guidelines for data use (Kandoth et al., 2013). 
Patient Selection 
All data were downloaded from the data portal on the TCGA site and 
parsed based on patients diagnosed with head and neck cancer.  All cases were 
diagnosed by board-certified pathologists and only patients with complete clinical 
history were considered.  Demographic data included sex, age at diagnosis and 
race.  Clinical data considered included clinical stage, overall survival, treatment, 
and anatomic site.  Clinical data including stage, grade, perineural invasion 
status, and AJCC TNM classification were also included (AJCC, 2002). 
Genomic mutational status and gene expression data were accessed from 
the TCGA data portal Synapse and downloaded using the R package synapse 
client.  TCGA data are organized in levels based on the extent of analysis and 
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normalization, with level 1 being raw data and level III data corresponding to 
published data.  All level III HNSC pancancer data (n=173) were assessed 
following normalization with a FDR of 0.03 and FC of 2.0 and p value <0.05 was 
considered significant. Data were queried for perineural (72 cases) versus no 
evidence perineural disease (101 cases).  All sequencing reads were analyzed 
by two methods: the DESeq2 package and EdgeR in the R package followed by 
additional Gene Set Enrichment Analysis (GSEA) (AJCC, 2002; Anders & Huber, 
2010; Mayburd et al., 2006).   Ingenuity pathway analysis (Ingenuity® Systems, 
http://www.ingenuity.com) a web-delivered application that enables the 
discovery, visualization, and exploration of molecular interaction networks in 
gene expression data, was utilized to analyze transcriptomic data (Mayburd et al. 
2006). 
Statistical Analysis 
All Categorical statistical analysis between clinical and demographic 
variables and Kaplan Meier Survival analysis was carried out in GraphPad 
PRISM 6.0.  A p-value <0.05 was considered significant. Ingenuity pathway 
analysis (Ingenuity Systems, USA) was utilized to determine significant pathways 
between PNI+ versus PNI- data downloaded from the Synapse Analyses.  All 
pathway data were analyzed using t-tests in silico.   
2.2 RESULTS 
Clinical Presentation of the TCGA HNC Cohort.  The overall incidence of PNI 
was 34% (n=124/366) in patients included in the clinical HNC TCGA pan-cancer 
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analysis while 66% (n=242/366) patients were PNI-negative. The median age 
and sex distribution of PNI+ vs. PNI- were 62.5 and 60 and 31% vs. 27% female 
and 69% vs. 73% male, respectively (Table 2.1).  Grade at diagnosis 
distributions were similar between perineural involvement versus unaffected 
lesions with Grade 2 being the most common (66% vs. 57%, respectively).   
Interestingly, PNI+ lesions presented with higher staging (Stage IVA; 67% vs. 
38%, PNI+ vs. PNI-).  Lymphadenopathy was also more common in PNI+ versus 
PNI- disease (38% versus 14%) although this might have been biased by a more 
extensive work-up of patients with PNI+ disease.  The more aggressive disease 
was also confirmed in the PNI cohort with an increase in higher tumor stage (≥T4 
71% vs. 43%, PNI+ vs. PNI-, respectively) and nodal involvement (49% vs. 21%, 
PNI+ vs. PNI-, respectively) (Table 2.2). 
Lesions of the oral tongue were the most commonly associated with 
perineural invasion (48% vs. 21%) while lesions of the larynx were most 
prevalent in the PNI- group (29% vs. 19%) (p<0.0001) (Table 2.3)  The types 
diverged when comparing incidence and PNI+ patients presented with 
diminished median survival of 2.45 years versus 4.36 years (p=0.0128; Wilcoxon 
Log-Rank) upon survival analysis (Figure 2.1).   
Analysis of Genomic Mutations in Perineural Invasion Sub-typed Patients. 
Because no studies have yet evaluated PNI disease versus disease without PNI 
for molecular mutations, we next assessed genomic mutations in patients with 
PNI+ and without PNI- lesions in the most aggressive disease (OS< 2.5 years).  
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38/105 (37%) PNI+ and 52/193 (27%) PNI- were found to cluster in poor 
survivorship of <2.5 years.   
Two hundred ninety-eight patients (n=298/366; 81%) had sufficient data 
from deep-sequencing and were considered for both PNI mutational and survival 
assessment.  Of these sequenced patients, 36% (n=105/298) were PNI+ and 
64% (n=193/298) were PNI- (Table II).  This incidence falls within the range 
reported 27-82% (Johnston, Yu, & Kim 2012; Mendenhall et al. 1989).  
Importantly, these data represent the largest assessed cohort to date with full 
matched clinical and mutational data sets. 
The median number of non-silent somatic mutations (NSM) were similar 
for each cohort (105 vs. 111, PNI+ vs. PNI-).  Furthermore, we observed a lower 
incidence of NSMs in HPV+ lesions when considering PNI+ (74) and PNI- (66) 
specimens as previously reported (data not shown).  Assessment between PNI+ 
tumors versus PNI- for non- synonymous gene mutations revealed a similar 
incidence in total events involving TP53 (87% and 88%), CDKN2A (24% and 
27%), NOTCH1 (24% and 25%).  Interestingly, PNI- tumors exhibited increased 
mutation rates for AJUBA (7 vs. 1 mutation) and EP300 (6 vs. 1 mutation) 
compared to PNI+ tumors while no specific drivers were observed in PNI+ 
tumors. 
Alterations in Gene Ontology Pathways in the Perineural Invasion Sub-
Type.  HNC is increasingly recognized as a heterogeneous disease with a 
spectrum of disease sub-types with accompanying mutations and gene 
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expression profiles, so we next considered variations in the transcriptome of 
PNI+ versus PNI- disease (Walter et al., 2013).  Analysis of raw RNAseq data 
included 73 PNI+ and 101 PNI- patients with complete raw data. Interestingly, top 
differentially expressed gene ontology (GO) pathways associated with G-protein 
coupled receptor signaling (GO:0007186; p= 2.56E-7), sensory perception 
(GO:0007600; p= 9.22E-7), dopamine metabolic process (GO:0042417; p= 
4.80E-6), neurological system process (GO: 0050877; p= 5.11E-6), and sensory 
perception of chemical stimulus (GO: 0007606; p= 4.37E-5) were observed in 
PNI+ cancers (Figure 2.2). To our knowledge, this is the first time these GO 
pathways have been associated with PNI+ disease.   
We next conducted pathway analysis to determine significant genes 
associated with PNI+ vs. PNI- genes. Interestingly, IPA analysis revealed a 
significant up-stream regulation by brain-derived neurotrophic factor (BDNF; 
p=8.3311E-6).  This trend was complemented by a positive heuristic for NGF 
signaling (3.667) which was a predicted positive regulator (Löw et al., 2008).  
Gene expression profiling revealed elevated neurotrophin and diminished 
inhibitory netrin signaling - two important neurogenic pathways  (Figure 2.3).  
Importantly, these data correlate with the poorly differentiated status observed in 
the PNI+ versus PNI- (Table 2.2).  Taken together, these target pathways 
represent novel mechanisms underlying the mutational status and gene 
expression profiles in PNI-associated cancers of the head and neck.  
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2.3 TABLES AND FIGURES 
Table 2.1. Patient demographics extracted from the TCGA data set with respect 
to the presence or absence of PNI. 
  
PNI+ 
n = 124 
PNI- 
n= 242 
 
Age 62.5 (19-90) 
60 
(24-87) 
  
n % n % 
S
ex
 Female 39 31% 66 27% 
Male 85 69% 176 73% 
 
     
A
lc
oh
ol
 
Neg 41 33% 74 31% 
Pos 81 65% 163 67% 
ND 2 2% 5 2% 
 
     
To
ba
cc
o 
Reformed > 15y 14 11% 42 17% 
Reformed ≤ 15y 38 31% 61 25% 
Current 44 35% 82 34% 
Lifelong 24 19% 50 21% 
ND 4 3% 7 3% 
 
     
Ly
m
ph
ad
en
op
at
hy
 
Neg 59 48% 108 45% 
Pos 47 38% 33 14% 
ND 18 15% 101 42% 
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Table 2.2.  Tumor Stage and Nodal status demonstrates more aggressive 
disease in PNI+ patients versus PNI- lesions. 
  
PNI+ 
n=124 
PNI- 
n=242 
Tumor Stage (T) 
 
  
 
  
≤ T3 36 29% 128 53% 
≥ T4 88 71% 104 43% 
  
 
  
 
  
Node Stage (N)         
≤N2a 63 51% 180 74% 
≥N2b 61 49% 51 21% 
ND 0 0% 11 5% 
 
 
 
 
 
 
 
 
 
 
 12	
Table 2.3.  Frequency of PNI in tumors at various anatomic sites reveals 
increased PNI in Oral Tongue Lesions. P<0.0001, χ2 .  
 PNI+ 
n=124 
PNI- 
n=242 
Anatomic Site     
AR 2 2% 8 3% 
BOT 2 2% 19 8% 
BM 6 5% 7 3% 
FM 16 13% 18 7% 
HP 2 2% 4 2% 
HPx 2 2% 2 1% 
L 0 0% 2 1% 
Lx 20 16% 69 29% 
OC 23 19% 33 14% 
Opx 0 0% 2 1% 
OT 50 40% 52 21% 
T 1 1% 26 11% 
 
Abbreviations:  AR: Alveolar Ridge; BOT: Base of Tongue; BM: Buccal Mucosae; 
FM: Floor of Mouth; HP: Hard Palate; HPx:  Hypopharynx; L: Lip; Lx: Larynx; OC: 
Oral Cavity; OPx:  Oropharynx; OT: Oral Tongue; T: Tonsil. N=343 patients. 
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Figure 2.1. Overall Survival is shorter in PNI-associated disease.  Patient survival 
was analyzed by Wilcoxon-Log-Rank analysis.  PNI-positive had a median 
overall survival of 2.46 (95% CI: 0.3913 to 0.8105) versus 4.36 (95% CI: 1.234 to 
2.555). 
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Figure 2.2. Gene expression data and pathway analysis from PNI+ tumors 
versus PNI- tumors. A) GO analysis reveals increased neurogenesis-related 
signaling as well as several neurologic related and sensory-related ontogenies; 
B) A waterfall plot of elevated transcripts reveals important neuropeptide 
(PCSK1N, PCDH9) and neurotransmitter signaling genes in PNI+ disease 
(CHRM5, CHRNA9).  
B 
A 
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Figure 2.3.  Pathway analysis shows increased neurotrophin and decreased 
netrin signaling in PNI+ HNC.   
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2.4 DISCUSSION 
Perineural disease is clinically associated with poor outcome, difficult 
management, and brain metastasis in HNC; however, the mutations and gene 
expression patterns which differentiate perineural association versus local 
invasion are largely unknown.  Our analysis confirms a poor prognosis in 
association with the perineural invasion in the largest fully sequenced cohort to 
date.  While the mutational spectrum was similar between these sub-types and 
the number of non-silent mutations, PNI+ lesions were more aggressive clinically.  
We also observed a higher incidence of mutations in AJUBA and EP300 in non-
perineural invasion-associated disease (PNI-).   AJUBA encodes a LIM protein 
that interacts with critical regulators of epithelial to mesenchymal transition 
(EMT), a key regulator of invasiveness in HNC.  LIM proteins are co-repressors 
of E-Cadherin via Snail family transcription factors (Langer et al., 2008).  EP300 
encodes a histone acetyltransferase protein that has recently been implicated in 
EMT and hypoxia (Chen et al., 2013).  The associations between mutations in 
EMT-related genes in PNI suggest an alternative mechanism to traditional 
invasiveness in perineural involvement in HNC. These findings suggested to us a 
divergence in the expression profiles of the PNI+ tumors versus the tumors with 
no perineural involvement.  
We next interrogated level III RNAseq data for difference in the 
transcriptome and revealed involvements of neurogenesis and nervous-system-
related pathways in HNC.  Recent genomic studies have greatly advanced the 
number of clinically actionable targets in HNC (Kandoth et al., 2013); Walter et 
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al., 2013; Stransky et al., 2011; Agrawal et al., 2011; Tamborero et al., 2013).   
Our unique study focused on Gene Set Enrichment Analysis (GSEA) and 
pathway analysis in exploring the importance of differential gene expression in 
perineural versus non-perineural disease.  Various neurotrophic ontogenies 
which centered around cholinergic signaling, sensory perception in the periphery, 
and neurotrophin signals were significantly implicated.  The translational 
importance of these findings is corroborated by recent studies that have 
demonstrated an emerging role of the peripheral nervous system in tumor control 
(Magnon et al., 2013).  We also discovered a decrease in the inhibitory netrin 
receptor UNC-5 which serves as a repulsive molecule for neuronal axons in the 
periphery (Löw et al., 2008). Taken together with the increases observed in 
neurogenesis and neurogenic GO pathways, these decreases in signals that 
inhibit netrin action indicate that signals that stimulate innervation are enhanced 
in perineural disease.  This hypothesis is further supported in lesions of the head 
and neck where perineural involvement, and the opportunity for tumors to nerves 
are high (Johnston, Yu, & Kim, 2012;Mendenhall et al., 1989; Lanzer et al., 
2014). A better understanding of the molecular mechanisms pathways which 
drive aggressive PNI behavior and neurogenic spread are of great significance 
for our efforts to decrease the risk of locoregional failure and metastasis.  
In addition to the confirmation of clinical studies of PNI in HNC, these data 
hold translational importance for biomarker development and therapeutic targets 
for better management of perineural invasion-associated aggressive disease. 
Perhaps most actionable are the neurotrophin-related pathways implicated in this 
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unsupervised analysis.  It has previously been demonstrated that neurotrophin 
activity is associated with increased invasiveness, poor outcomes, and 
resistance to chemotherapy (Søland et al., 2008; Yilmaz et al., 2010).  Genomic 
patient-based studies have also implicated epigenetic silencing of neurotrophin-
driven pathways in HNC (Panizza et al., 2013).  These data complement other 
studies in demonstrating the genetic and gene expression differences between 
PNI+ and PNI- lesions and suggest targets for future investigation (Agrawal et al., 
2011; Panizza et al., 2013; Kostareli et al., 2013; Kolkythas et al., 2010).  It will 
be of great interest to investigate these targets in larger well-designed studies 
where PNI is specifically investigated by imaging, pathologic staging, and 
molecular analysis. 
The aggressive nature of PNI-associated disease is further indicated and 
the need for actionable pre-clinical targets and surrogate markers – to 
complement conventional imaging studies and anatomic pathology – is 
paramount.  Translating these markers into clinically actionable subtypes holds 
promise in the management of head and neck disease. 
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CHAPTER 3 
MASSIVELY PARALLEL SEQUENCING IDENTIFIES NOVEL 
MUTATATIONS IN NEUROENDOCRINE HNC  
Merkel Cell Carcinoma (MCC) is a relatively rare neuroendocrine cancer with 
poor prognosis that is seen with increasing frequency in the USA (Schrama et al. 
2012). MCC often presents in the sixth decade of life in patients of predominantly 
Caucasian ethnicity. Tumors arise in UV-exposed regions of the head and neck, 
upper thorax and extremities (Lemos et al. 2007).   The disease often presents as 
nonpainful nodules with local invasion in immunocompromised patients. 
Recently, a great deal of attention has focused on MCC due to the discovery of a 
viral pathogenesis for the disease (Feng et al. 2008). 
Merkel cell carcinoma is a neuroendocrine neoplasm involving 
somatosensory cells present within the epidermis. Merkel cells, also known as 
Merkel-Ranvier cells or APUD cells (apparently unrelated endocrine cells) 
contain neuroendocrine granules and detect coarse tactile stimuli. Their 
distribution occurs throughout the basal epidermis in both glabrous and haired 
skin including the nose, lips, and gingiva (Winkelmann & Breathnach 1973).  
Merkel cells often juxtapose hair follicle bulges and Langerhann’s cells, and are 
increased in mechanosensory and tactile-sensory regions. As such, these cells 
are innervated by Aα nerve fibers of the peripheral nervous system (Boulais & 
Misery 2007) This compartment is innervated at approximately 50 cells per nerve 
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bouton and is principally served by mechano- (αβ), proprio(γ and C)-, and 
nociceptive (Aα and C) fibers (Lumpkin & Bautista 2005).  Merkel cells are 
putative mechanosensory cells of the epidermis; however, the direct mechanistic 
role they play in neoplasia remains poorly defined at the molecular level.   
MCC is considered a nonmelanotic skin cancer and has only within the 
past several decades gained better definition.  MCC was first described by Cyril 
Toker as trabecular carcinoma of the skin and its diagnosis was greatly facilitated 
by the advent of reliable cytokeratin 20 immunohistochemical staining in the early 
1990’s (Toker 1972; Moll et al. 1992; Erovic & Erovic 2013).  Additionally, MCC 
lesions are positive for various granular neuroendocrine markers including 
chromogranin A and synaptophysin. Interestingly, in 2008 a DNA polyomavirus 
was identified and classified as the Merkel cell polyomavirus (MCPyV) that has 
since been detected in the majority of MCC cases (Feng et al. 2008; Erovic et al. 
2013).  Infection with MCPyV is believed to be associated with nearly 100% of 
MCC. Reactivation of latent MCPyV in immunocompromised individuals has 
been posited as an essential underlying pathogenic mechanism (Wiedinger et al. 
2014). 
Merkel cell carcinomas are clinically challenging to manage and often 
recur locally within a short time following initial resection. Management often 
includes broad excision followed by concurrent chemoradiation including 5-
Fluoroxyuridine (5-FU) and platinum-based regimen and there are currently no 
FDA-approved targeted therapies.   
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The management and understanding of MCC has remained limited due to 
the absence of deep sequencing studies to determine potential mutations within 
these tumors (Rodig et al. 2012; Nardi et al. 2012).  To this end, we have 
implemented a massively parallel sequencing approach covering over 400 
cancer-related genes in an attempt to further dissect some of the critical 
oncogene drivers in a cohort of MCC patients treated at our institution. 
3.1 MATERIALS AND METHODS  
Patient Selection 
All aspects of the study were approved by the William Jennings Bryan 
Dorn VA Medical Center research department and institutional review board.  
Retrospective chart reviews conducted from 1993 to 2013 revealed a total of five 
patients diagnosed and treated for neuroendocrine Merkel cell carcinoma.  
Patient demographics, clinical metrics, history, progression free survival, and 
overall survival were analyzed. 
Diagnostic Pathology 
All cases were confirmed by a board certified pathologist for 
histopathological small cell differentiation as well as cytokeratin 20 (CK20), 
Synaptophysin (Syn), and Chromogranin A (CgrA).  Additionally, Merkel cell 
polyoma virus (MCPyV) large T antigen was analyzed in slides from the 
retrospective cases and reviewed. 
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DNA Extraction and Massively Parallel Sequencing of 400 Cancer-related 
Genes. 
Genomic DNA was extracted from archival formalin fixed paraffin 
embedded (FFPE) utilizing a FFPE DNA extraction kit as per manufacturer’s 
recommendations (Qiagen).  Briefly, tissue was sectioned at 4 µm with 
approximately 3 sections per block and deparaffinized in xylene.  Tissue was 
then washed with ethanol and the sedimented samples were separated from 
residual solvent by evaporation.  Samples were lysed in lysis buffer with 10% 
DNA Proteinase-K at 55 °C for 60 minutes with an additional reversal of DNA 
cross-links at 90 °C for 60 minutes.  Lysed tissue was then added to DNA 
columns and submitted to a series of washes with elution in water. 
AmpliSeq (Life Technologies) DNA libraries were then prepared following 
the manufacturer’s instructions.  Briefly, for each specimen, 40 ng of DNA was 
divided amongst four multiplex primer pools containing 10 ng of template 
DNA.  Approximately 4000 target amplicons were amplified in each pool using 
the AmpliSeq Comprehensive Cancer Panel (CCP) primers and standard 
AmpliSeq manufacturers protocol.  These amplicon pools were then combined 
and put through the remainder of the library preparation per the standard 
protocol.  Libraries were diluted to 100 pM, combined in equal amounts, and 
used for template preparation of Ion Sphere Particles (ISPs) per the 
manufacturer’s instructions.  Prior to sequencing, the percent of templated ISPs 
was verified to lie between 10% and 25%, ensuring that the appropriate amount 
of library was added during the template preparation step.  ISPs were then 
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enriched and deposited on to a Proton PI sequencing chip per the instructions 
given in the Ion PI Sequencing 200 Kit user guide.  Six CCP libraries were 
sequenced simultaneously across two Proton runs, yielding between 15.5M and 
28M aligned reads per library.  Alignment and Variant identification was 
performed using Torrent Suite version 3.6.2 using high stringency somatic 
detection settings. 
Statistical Analysis 
All statistical analysis was carried out using the Torrent Suite version 3.6.2 as 
described above. 
3.2 RESULTS 
Patient Demographics and Clinical Course. Retrospective chart reviews 
conducted from 1993-2013 identified 5 patients treated at our institution and 
diagnosed with Merkel cell carcinoma.  Patients fell within the typical diagnostic 
criteria with all being Caucasian males >60 years of age (Mean: 80, 61-89) 
(Table 3.1).  Patients were referred to the clinic following identification of 
characteristic MCC nodules.  Interestingly, 80% (4/5) patients presented with 
past history of colon adenocarcinoma and actinic keratosis (Table 3.1). One 
patient was incidentally diagnosed and treated with wide-band excision of the 
forehead. Three patients underwent direct biopsy with subsequent subtotal 
resection and 4/5 patients underwent salvage gross total resection.  Post-
operative scans demonstrated marked disease reduction.  Two patients 
completed follow-up radiation therapy while one patient underwent chemotherapy 
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alone.  Eighty percent of patients (4/5) presented with history of skin cancer and 
dermatological disorders at diagnosis (Squamous Cell Carcinoma: 2/5;40%; 
Melanoma: 1/5; 20%; Actinic Keratosis 4/5; 80%). 
Patient Pathology. All diagnoses were confirmed by a board certified pathologist 
with chromogranin A (CgrA), synaptophysin (Syn), and cytokeratin 20 (Ck20) all 
common pathological markers of neuroendocrine Merkel cell carcinoma.  All 
cases were positive for CgrA, Syn, and CK20 (Figure 3.1; Table 3.2).  
Additionally, where available, tissue was stained for the surrogate marker 
MCPyV large T antigen which was present at the reported frequency of 75% of 
the cases with the most commonly used antibody (3/4 specimens) (Figure 3.1f). 
Massively Parallel Sequencing of Patient Samples. Adequate tissue for DNA 
extraction was available from four archival patient specimens and the blocks 
were selected for further analysis utilizing the Ion AmpliSeq Comprehensive 
Cancer Panel  (CCP) on Ion Proton instrumentation to assess somatic mutational 
spectra.  The CCP is a multiplex PCR-based 409 gene targeted panel with rapid 
high-throughput assessment of mutations based on the Wellcome Trust Sanger 
Institute’s Cancer Gene Census.   Within our data set, we called an average of 
4606 variants per patient (n=4; 4472-4762).  One sample was found to maintain 
elevated variants at 12226 called variants (Appendix B).  This is not unexpected 
as this specimen was processed in higher concentration formalin had been 
archived for a prolonged period (Srinivisan et al. 2002; Williams et al. 1999). 
However, concomitant variants and deleterious mutations were detected within 
all genes that were interrogated. 
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Gene Mutational Spectrum Analysis. Next-generation sequencing analysis 
revealed a spectrum of mutations which were present at high mutant allele 
frequencies (MAF).  The CCP contains exon-specific probes which specifically 
avoid homopolymers and we corrected for the possibility of G>C and T>A 
transversions by focusing only on high MAFs.  Due to the retrospective nature of 
the cohort, matched blood samples to determine somatic mutational status were 
unavailable.  We therefore focused our analysis only on the most significant and 
penetrant mutations within our population. 
Nonsense mutations. Several nonsense mutations were detected in 75% of 
patients (n=3/4) within the fourth exon of PDE4DIP (Table 3.3).  This gene 
encodes phosphodiesterase-4 interacting protein or myomegalin, a protein 
commonly associated with myelodisplastic disorders.  Interestingly, 
phosphodiesterase-4D is a key interacting enzyme responsible for downstream 
inhibition of cyclic adenosine mono-phosphate (cAMP)-mediated activity within 
neural tissues (deVente et al. 2006). Other mutations in critical DNA damage 
response genes (PRKDC (50%; 2/4) were also detected but occurred at lower 
confidence MAFs (MAF=48.25 and 2.65, respectively) (Figure 3.3;  Appendix B).  
Insertion/Deletions and Missense Mutations.  We next focused our analysis 
on single nucleotide polymorphisms (SNPs) resulting in missense mutations with 
a high MAF in our cohort (n= 45 Genes; MAF >86%).  Importantly, many of these 
mutations are validated within functionally important coding domains based on 
the comprehensive cancer panel. A 1 bp indel (insT) was present in exon 14 of 
MLL3 at high allelic frequency across all 4 samples, resulting in a frame-shift 
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mutation at tyrosine 816 (Figure 3.2B).   Because this mutation was present in all 
four samples, we wanted to ensure that this was not a systematic error in the 
sequencing data.  For example, Ion Torrent sequencing is susceptible to 
miscalling indels within homopolymer stretches due to the difficulty in resolving 
signal amplitudes for multiple bases of the same type (Margulies et al. 2005). We 
analyzed the mutation and demonstrated that the indel identified in all four 
samples does not reside within a homopolymer, thus reducing the possibility that 
this mutation is a systematic error (S2).  Furthermore, the coverage across this 
mutation was over 1000X in all samples, and there was no indication of strand or 
allelic bias. MLL3 encodes a nuclear-localized histone lysine-4 methyltransferase 
that is frequently deleted in myeloid leukemia and mutated in glioblastoma as 
well as pancreatic cancer (Balakrishnan et al. 2007).  
Additional analysis revealed consensus frame-shift mutations within a 
variety of genes associated with DNA damage repair and apoptosis.  A missense 
mutation in all of the samples at position 1053 (glycine to arginine) in the ERCC5 
gene associated with xeroderma pigmentosum (MAF: >99%; 3/4) and an 
additional missense within the same region 1080G>R (MAF: 99.13 1/4) was 
observed.  Intriguingly, this missense mutation is present upstream of the nuclear 
localization sequence and represents a highly conserved residue in the enzyme.  
ERCC5, also known as XR-5, is a critical regulator in the nucleotide excision 
repair pathway (NER) whereby it removes nucleotide adducts following chronic 
UV irradiation.  It has been noted that MCC is most prevalent in pale-skinned UV-
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exposed regions of the body wherein NER is critical to maintaining genomic 
integrity. 
We also observed a missense mutation at 298M>T (MAF:>99%; 4/4) in the 
aurora kinase β (AURKB) gene.   Aurora kinase beta (AURKB) is a co-factor 
critical to maintaining mitotic-integrity that is activated in response to UV 
irradiation at the centromere and over-expression has been demonstrated to 
preclude chromosomal aneuploidy in colon cancer (Schjolberg et al. 2009; Arora 
et al. 2012). Furthermore, AURK β interacts with survivin at the centromere which 
has recently been described as clinical target in MCC (COSMIC 2013).  An 
identical mutation in the large intestine has been documented in the AURK β 
gene and 3/4 of our patients intriguingly were treated previously for colon 
carcinoma (COSMIC) (Giampieri et al. 2013).   
Missense mutations were observed in several other DNA repair pathways 
including ataxia telangiectasia rad6 related (ATR; 4/4) within the ATRIP-binding 
domain and the associated ATRX (3/4).  This is an important regulator of cell 
cycle progression following DNA damage and ATRIP has been demonstrated to 
modulate the activity of ATR in initiating DNA damage repair (Figure 3.3). 
Single-nucleotide polymorphism of the thyroid stimulatory hormone 
receptor (TSHR) were synonymously identified at position 727 E>D (MAF: >98%).  
Mutations in BCL2L2, an anti-apoptotic factor related to the BCL-2 family, 
demonstrated a glutamine to arginine mutation at position 133 (MAF: >97%; 4/4). 
Synonymous mutations in the COL1A1 (1075T>A MAF: >99%; 4/4) gene were 
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also detected with high frequency (Giampieri et al. 2013). Taken together, these 
germline mutations hold potential as novel targets that have not been previously 
described in MCC. 
3.3 TABLES AND FIGURES 
Table 3.1.  Patient Demographics, Pathology, Treatment Parameters, and 
Relevant Clinical Comorbidities. 
 
*Colon Polyps. Abbreviations:  Bx-Biopsy; Chemo-Chemotherapy; Radio-
Radiotherapy; STR-Subtotal Resection; Ing-Inguinal; ND-Neck Dissection; GTR- 
Gross Total Resection; SCC- Squamous Cell Carcinoma; BCC- Basal Cell 
Carcinoma; Mel -Melanoma; CaP- Prostate Carcinoma 
 
Demographics Pathology Therapy Comorbidities 
Pat 
n=5 
Sex/ 
Race 
Age Site Stage/
Grade 
Resecti
on 
Status 
1: Bx 
2: STR 
3: ND 
4: GTR 
Treatment 
1: Chemo 
2: Radio 
Alcohol/ 
Tobacco 
1:  
Nonuser 
2: 
Occasion
al 
3: 
Chronic 
4: Quit 
A
ct
in
ic
 K
er
at
os
is
 
C
ol
on
 C
an
ce
r 
Other 
Malign
ancy 
1: 
SCC 
2: 
BCC 
3: Mel 
4: CaP 
I M/C 61 Abd  1,2 - 2/3 X X 1,4 
II M/C 82 Neck T2N1M
0/IIb 
1,3(x2),
4 
1 1/1 X X 1,2 
III M/C 89 Ing  1 2 1/1   1,2,3 
IV M/C 85 Head T1N0M
0/Ib 
1,4 2 1/4 X X 1,2 
V M/C 82 Neck  2,3 - 1/1 X   X* 1,2 
Average/N 79      4(80%) 4(8
0%) 
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Table 3.2.  Immunohistochemical markers of Neuroendocrine MCC 
Specimen Syn CgrA CK20 MCPyV LT 
I + + + + 
II + + + + 
IV + + + + 
V + + + + 
Abbreviations: Syn:  Synaptophysin; CgrA: Chromogranin A; CK20: Cytokeratin 
20; MCPyV LT: Merkel cell polyomavirus Large-T antigen. 
 
 
 
 
Table 3.3.  Nonsense mutations in PDE4DIP (3/4; 75%). 
Specimen Coverage Mutation AAΔ MAF SNP 
db 
Ref 
I - - - - - 
II 1922 C>T 560W>* 22.1  
IV 1135 G>AG 622R>* 38.84 rs1778111 
 
V 1813 C>CT 506W>* 30.34 rs1698683 
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Figure 3.1.  Representative diagnostic MCC anatomic pathology. a) H&E 10x, b) 
H&E 40x, c) Synaptophysin, d) CK20, e) Chromogranin A, and f) (MCPyV Large 
T Antigen Immunohistochemistry.  40x unless otherwise noted; bars represent 
200 microns. 
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Figure 3.2. Mutations (MAF>86%) within the 4 sequenced samples. A) 
Distribution of mutations within various genes on the CCP. B) MLL3 gene with 
corresponding insertion in exon 14 within plant homeodomain (PHD) just up-
stream of the high mobility group (HMG). 
 
 
 
B 
A 
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Figure 3.3.  Overall missense mutations within the cohort of patients. Samples 
with missense mutations are noted in blue while non-mutated samples appear in 
red. 
3.4 DISCUSSION 
Several well-powered studies evaluating the mutational spectrum in 
Merkel cell carcinoma have recently been conducted; however, these studies 
1 2 3 4
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have not yet deeply sequenced tumors for a predicted mutational spectrum 
(Rodig et al. 2012; Nardi et al. 2012; Kartha & Sundram 2008).  Within our 
focused cohort, we implemented a targeted 409-gene screen in four patients and 
demonstrated potential targets with relevance to Merkel cell disease.  
Importantly, we observed frequent nonsense mutations in PDE4DIP – better 
known as myomegalin – within 3/4 of the patients included in this study.  
Myomegalin is a predicted oncogene and gain of function mutations have been 
implicated in myeloproliferative disorders.  All nonsense mutations occurred 
within the fourth coiled domain directly upstream of a breakpoint site within 
known PDE4DIP-PDGFRB fusion (Wilkinson et al. 2003). 
Missense mutations within key DNA damage and apoptosis genes were 
also detected.  H3K4 histone methyltransferase MLL3 demonstrated an insertion 
in our study in all the patients included in the study.  This mutation adds a 
tyrosine residue upstream within the highly conserved plant homology domains 
(PHD) which flank the transactivation domain and are important in CREB-
mediated gene expression (Ernst et al. 2001).  Interestingly, MLL3 mutations 
have been previously demonstrated in other aggressive neuroendocrine tumors 
including pancreatic neoplasms as well as medulloblastomas (Parsons et al. 
2011). Furthermore, MLL1 – a close analog of MLL3 and component of the 
methyl-tranferase complex – is essential for post-natal neurogenesis indicating a 
potential overlap of H3K4 methylation and over-activation in the neuroendocrine 
compartment (Lim et al. 2009).  Our study demonstrated a potentially novel 
missense mutation in MCC within the ERCC5 gene proximal to the nuclear 
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localization sequence which was present in our cohort predominantly as a 
glycine to arginine substitution.  In vitro work has recently linked ERCC5 
signaling with ATR-ATRIP signaling in DNA damage responses to UV.  In 
addition, UV induced damage repair pathway is known to activate aurora-kinase 
β which interacts with downstream BCL2L2 and anti-apoptotic pathways.  
Therefore, it will be of great interest to determine whether loss of function at 
these loci is incurred with these mutations (Lindsey-Boltz et al. 2014).  In our 
cohort, a glutamic to aspartic acid mutation at position 727 of the TSHR gene 
was present in high allelic frequency. Interestingly, recent studies have indicated 
this SNP, denoted as rs1991517, to be associated with enhanced risk for thyroid 
cancer, DNA damage and RET-oncogene polymorphism in populations exposed 
to ionizing radiation (Sigurdson et al. 2009). 
BCL2L2 is an antiapoptotic gene of great interest to oncologists. BCL2L2 
is up-regulated downstream of NFκβ-mediated pro-survival signaling and is 
involved in nervous tissue responses to BDNF and NGF (Middleton et al. 2001).  
Interactions between UV-induced DNA damage response and apoptotic 
pathways (ERCC5, AURKβ, BCL2L2) and receptor responsive elements 
(PDE4DIP and TSHR) could provide potential preclinical targets for validation in 
MCC. 
Randomized clinical trials incorporating targeted therapies such as 
pazopanib or imatinib are hindered by the rarity of MCC, but are necessary to 
improve outcomes (Desch & Kunstfeld 2013).  Various immunotherapy trials are 
underway evaluating the utilization of IL-12 gene therapy and Large T Antigen 
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priming in MCC.  Additionally, the potential PDGFRA-PDE4DIP fusion previously 
reported could also represent a potential clinical target.  However, Swick and 
colleagues considered PDGFRA-KIT expression in a focused cohort of 23 tumors 
demonstrating a 95% and 65% expression of these markers, respectively, but 
found no activating mutations (2013). It will be of great interest to determine if the 
DNA damage and pro-survival pathways play a role in a larger cohort of this 
aggressive neuroendocrine cancer.  
Within our small cohort of MCC cases, various genetic mutations were 
detected with potential relevance to MCC pathogenesis. UV exposure is a risk-
factor for MCC and we describe a mutation in ERCC5, a gene which encodes a 
protein important in UV induced nucleotide excision repair (NER) and that is 
implicated in xeroderma pigmentosum (Senchenkov et al. 2007; Grotz et al. 
2012).   All of the patients sequenced in this cohort demonstrated other UV-
associated dermatological conditions including actinic keratosis and skin cancers 
(Ferrara et al. 2010; Werner et al. 2013).  Additionally, we found mutations in 
PDE4DIP, a gene which encodes a regulatory binding protein important in neural 
tissue associated calcium-mediated cAMP signaling.  We also detected a high 
frequency of mutations within genes important in maintaining genomic stability 
including MLL3, AURK β, and BCL2L2. Further validation of these genes in 
larger associational cohorts and their significance as potential therapeutic targets 
and/or clinical prognostic indicators will better direct clinical decision and 
understanding of the underlying molecular drivers of Friedrich Sigmund Merkel’s 
carcinoma (Merkel 1875).
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CHAPTER 4 
DEEP LEARNING AND MOLECULAR PATHWAYS IDENTIFY 
TRANSLATIONAL TARGETS IN HNC 
Tumors of the upper aerodigestive tract are closely associated with the 
peripheral nervous system.  This likely contributes to the complex heterogeneity 
often appreciated in neoplasms that originate in the oropharynx, nasopharynx, 
and larynx.  The etiological risk factors classically implicated in these diseases 
include genetics, tobacco and alcohol use, and infection with oncogenic viruses 
and co-morbid immunosuppression (Ang et al. 2010; Leemans et al. 2011; 
Kreimer et al. 2013). The oropharynx accounts for approximately 60% of all 
newly diagnosed aerodigestive tract tumors where exposure to oncogenic 
viruses such as the human papillomavirus (HPV) plays a significant role in 
disease progression (Hillbertz et al. 2012). 
Recent evidence points to a significant role of neurotrophin signals from 
the peripheral nervous system in normal and neoplastic trans-differentiation (Fan 
et al. 2004, Bronzetti et al. 2006, Nakamura et al. 2007).  The low-affinity nerve 
growth factor (p75NTR; LNGFR; CD271) is the principal neurotrophin receptor 
that signals via the nerve growth factor (NGF) (Lu, Pang, Woo 2005).  These 
receptors classically heterodimerize with tyrosine kinases (Trk) A,B, and C 
promoting a diversity of receptor/ligand induced signals.  p75NTR and various 
neurotrophins (Nerve growth factor (NGF); Brain-derived neurotrophic factor 
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(BDNF); Glial cell-derived Neurotrophic Factor (GDNF); Neurotrophin 3 (NT-3) 
and Neurotrophin 4 (NT-4)) are active in maintaining the somatosensory 
functions of the oropharynx (Bronzetti et al. 2006, others).  Cancers of the head 
and neck are aggressive and often associate with the peripheral nervous system 
in perineural invasion and are associated with brain metastasis in as many at 6-
18% of all cases (Tse 2013; Ruzevick et al. 2013).  Recent studies have 
suggested an epigenetic role for TrkA and B and their cognate ligands in HNC 
that differentiates HPV-driven from HPV negative disease (Kostareli et al. 2013).  
Additionally, TrkB has been demonstrated to predict poor overall survival in 
oropharyngeal cancers and has been proposed as a target for clinical 
intervention (Kupferman et al. 2010; Lee J et al. 2012). 
Taken together, the role that these neurogenesis-related drivers play in 
the pathogenesis of virally induced head and neck cancer might hold important 
insight into the molecular biology of the underlying tumors.  We propose that 
these targets might provide a rationale for the involvement of the peripheral 
nervous system and offer potential targets for therapeutic intervention. 
4.1 MATERIALS AND METHODS 
Patient Specimen Collection 
All patient specimens were collected under informed consent of the patient 
and the approval of the institutional review boards of the Medical University of 
South Carolina and the Dorn VA Medical Center. 
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DNA, RNA, and Protein Expression Analysis 
DNA, RNA, and Protein were collected as previously described (Tomar et 
al. 2016).  Briefly, flash frozen or RNA-later preserved surgical specimens were 
de-identified and cryostored at -80 C and -20 C, respectively.  Nucleic acids and 
protein were collected using All Prep as per manufacturer’s protocols (Qiagen).  
Nucleic acids and proteins were assessed for quality and quantity by 
spectrophotometer for all downstream analyses.  cDNA was generated using 
iScript reverse-transcriptase for all patient samples (BioRad, USA).   
HPV-Serotyping and Activity Analysis 
All samples were typed for HPV-DNA using a linearized reverse 
hybridization assay as previously described (INNO-LiPa, Fujirebio) as previously 
described.  Briefly, gDNA was globally amplified using primers directed to the L1 
region od 27 HPV types.  The resulting amplimers were then hybridized to linear 
indicators and results were quantified.  HPV-Activity was assessed by 
quantitative real-time PCR (qPCR) as described in Tomar et al. 2014.  Briefly, 
primer sequences for HPV16 E7 (Forward: 5’ — CCG GAC AGA GCC CAT TAC 
AAT – 3’ 5’ — CCG GAC AGA GCC CAT TAC AAT – 3’; Reverse:  5’ — ACG 
TGT GTG CTT TGT ACG CAC – 3’) were utilized to amplify cDNA synthesized 
on the template of tumor-derived RNA (Lamarcq et al. 2002). qPCR conditions 
were as follows: initial denaturation (95°C x 180 s.) followed by 40 iterative cycles 
of denaturation (95°C x 10 s) and primer annealing and elongation, respectively 
(60s).   
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Agilent cDNA Microarray Analysis 
Microarray experiments were performed using the Agilent Technologies 
(Santa Clara, CA) platform. Total RNA samples were amplified and labeled using 
Agilent’s Low Input Quick Amp Labeling Kit according to the manufacturer’s 
recommendations. Briefly, mRNA contained in 200 ng of total RNA was 
converted into cDNA using a poly-dT primer that also contained the T7 RNA 
polymerase promoter sequence. Subsequently, T7 RNA polymerase was added 
to cDNA samples to amplify the original mRNA molecules and to simultaneously 
incorporate cyanine-3 labeled CTP into the amplification product (cRNA). In the 
next step, labeled cRNA molecules were purified using Qiagen’s RNeasy Mini Kit 
(Valencia, CA). After spectrophotometric assessment of dye incorporation and 
cRNA yield, samples were stored at −80°C until hybridization. Labeled cRNA 
samples (600 ng) were hybridized to SurePrint G3 Human Gene Expression 
8×60K v2 Microarrays at 65°C for 17 h, using Agilent’s Gene Expression 
Hybridization Kit according to the manufacturer’s recommendations. After 
washes, arrays were scanned using a High Resolution Agilent DNA Microarray 
Scanner and images saved in TIFF format. 
 
Deep Learning Validation of Microarray Gene Expression 
Data were extracted from images with Feature Extractor Software version 
10.7.3.1 (Agilent) where background correction was also performed. 
Background-corrected data were uploaded into GeneSpring GX version 11.5.1 
for analysis. In this process, data were log2 transformed, quantile normalized and 
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base line transformed using the median of all samples. Then, data were filtered 
by flags in a way that 75% of the samples in at least one of the treatment groups 
have a “detected” flag. Differentially expressed genes were determined by 
analysis of the data using the non-parametric Mann-Whitney unpaired test. Cutoff 
values of 0.02 and 2 were used for p-value and fold-change, respectively. Gene 
ontology (GO) pathway analysis and hierarchical cluster analysis were also 
performed with GeneSpring. For the hierarchical cluster analysis, Euclidean 
similarity metrics and Wards linkage rule were used along with Kruskal-Wallis 
non-parametric ANOVA. Kaplan-Meier survival curves were generated using 
GraphPad PRISM version 6.0 (GraphPad, Software, La Jolla, CA). A p-value of 
0.05 or less was considered significant. 
 
Immunohistochemistry Validation of HPV+ vs. HPV- Cancers 
Formalin-fixed paraffin embedded (FFPE) samples were cut at 5 µm 
thickness on a microtome and antigen-recovered at 75 oC.  Specimens were then 
probed using antibodies to NGFR (Clinical Pre-dilute; Biocare), POU4F1 (1:200; 
Millipore) NEFH (1:1000; Biocare), Ki67 (1:2000, Cell Signaling Technologies).  
DAB chromogen was utilized for detection of antigen (Abcam).  Freshly resected 
HNC tumor lesions were flash frozen and embedded in OCT mounting medium.  
Specimens were fixed in cold methanol, serially sectioned on a cryostat at 7 µm 
and incubated with anti-mouse NEFH-HRP (1:500; Biocare) to visualize 
innervation of the tissue specimens. 
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4.2 RESULTS 
HPV Positive and HPV Negative Tumors Differentially Express 
Neurogenesis-Related Genes.  Craniofacial development occurs early in 
embryonic development and the connective tissue of the head and neck 
originates from the neural crest.  A stem cell niche of de-differentiated basal oral 
keratinocytes (bOK) are maintained to promote wound healing and tissue 
regeneration throughout life (Jones & Klein 2013). This niche has been 
suggested as the target of oncogenic HPV viruses within the oral mucosae and 
transformation and neoplasia are associated with poor differentiation of the 
epithelium (Syrjänen 2010).  These slowly proliferating (Ki67lo) cells express the 
NGFR (p75NTRhi) and cytokeratins (CK 5/14/19) as well as other important 
developmentally regulated genes and are the targets of oncogenic 
papillomaviruses (Leemans et al. 2011).  We discovered a preponderance of 
known and novel neural-related genes in our data set when analyzing differences 
between HPV driven and HPV- tumors (Figure 4.1; Table 4.1).   We further 
assessed these neural-associated genes in the Walter et al. TCGA data-set and 
discovered a significant concordance in expression (Figure 4.2) (Walter et al., 
2013).  These data led us to further consider the role HPV16 infection might play 
in de-differentiated bOKs and activation of neural pathways in head and neck 
cancer. 
Infection with HPV16 suggests a de-differentiated and neurogenic program 
in cancers of the head and neck. The abundance of significantly up-regulated 
neural genes concomitant with viral infection suggested to us that this might be 
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an important mechanism in the pathogenesis in HNC.  We chose to focus our 
analysis on the peripheral nervous system (PNS) and gene components of the 
sympathetic and somatosensory compartments.  We found significant differences 
when comparing HPV16 positive versus HPV16 negative expression which 
included GABA receptor Pi (GABRP (40 Fold)), Glutamic acid decarboxylase 1 
(GAD1(10 Fold)) Single-minded (SIM2 (9.8 Fold)), NGFR (p75NTR (6.7 Fold)), 
POU4F1 (POU4F1 (6.2 Fold)), neurofilament heavy chain (NEFH; 200 kDa) in 
HPV positive and HPV patients amongst others (Figure 4.3).   
Anatomic Markers of Peripheral Nerves are Up-regulated in HPV+ HNC 
pathology.  To validate these gene expression changes in HPV+ cancers, we 
next examined the expression of NEFH.  Because NEFH was up-regulated in our 
original dataset in HPV+ versus HPV- cancers and it is considered a gold-
standard immunohistochemical marker for peripheral nerves, we performed IHC 
staining on HPV+ versus HPV- tumor samples.  Utilizing clinical-grade 
antibodies, we stained for NEFH and observed a statistically significant increase 
in the number of cases that were positive for NEFH in HPV+ versus HPV- 
cancers (42% versus 22%, respectively; p<0.05%, t test, Figure 4.4A).  
Furthermore, our IHC study indicated an increase in peritumoral invasion 
microanatomy in HPV+ HNC (Figure 4.4B) versus HPV- cancers. 
Nerve growth factor receptor (NGFR) is Up-regulated in HPV+ HNC.  To 
begin to determine a functional role and to validate machine learning data, we 
next evaluated the expression of the low-affinity neurotrophic receptor, NGFR.  
Because NGFR is a cytoplasmic tyrosine kinase receptor, we utilized clinically 
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validated antibodies to assess whether gene expression changes observed were 
present in HPV+ versus HPV- cancers. Our data demonstrated a marked 
difference in the prevalence of NGFR expression in HPV+ HNC versus HPV- 
cancers (75% versus 8%, respectively; Figure 4.5A. p=0.0078).   
These factors have previously been demonstrated to play a role in HNC 
(p75NTR), HPV-associated malignancies (POU4F1), and esophageal cancers 
(NEFH), respectively.  We observed an abundance of targets downstream of 
critical neural crest transcription factors (see schematic representation in Figure 
4.6). Together, these data suggested that these neural-related genes might be 
targets in the pathogenesis of virally induced HNC.   
4.3 TABLES AND FIGURES 
Table 4.1.  Selected neurogenesis-related genes up-regulated > 2.0 fold in HPV+ 
versus HPV- HNC.  
Gene FC vs. HPV- 
Neural Crest Markers 
POU4F1 6.02 
ISL1 10.24 
NGFR 6.52 
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Perineural Invasion Markers 
PTN 7.58 
MDK 2.85 
SRGAP3 5.34 
Pain-Receptors 
TRPV6 5.27 
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Figure 4.1. HPV+ and HPV- Tumors have distinct gene expression profiles.  
Unsupervised hierarchical clustering demonstrates divergent gene expression 
profiles in HPV+ vs. HPV- tumors p<0.02; FC ≥ 2 Mann-Whitney. 
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Figure 4.2.  Key neural crest genes are mutated in an independent TCGA HNC 
dataset. (A) Screenshot from TCGA HNC dataset implicates NGF activation in 
P75NTR.  (B) Mutations in HPV+ HNC that are significant for NGFR and TrkA 
signaling and are associated with the neurotrophin signaling cascade.  p<0.05; 
FC ≥ 2 Mann-Whitney, Student’s t-Test. 
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Figure 4.3. Neurogenesis-related genes associated with neurotrophin signaling, 
neurotransmitter signaling, and neuritogenesis are significantly overexpressed in 
HPV+ cancers versus HPV- cancers. 
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Figure 4.4.  HPV+ tumors demonstrate increased interactions with the peripheral 
nervous system as labeled by NEFH. (A) Percentage of HPV+ and HPV- cancers 
that stain positive for NEFH (Mann-Whitney t-test, *p= 0.0404). (B)  40x 
representative images of NEFH staining in HPV+ and HPV- cancers.  
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Figure 4.5.  HPV+ tumors have high NGFR expression more often than HPV- 
tumors (A) % of HPV+ and HPV- cancers with positive NGFR staining (Wilcoxon 
t-test p=0.0078) (B) 40x representative images of NGFR staining in HPV+ and 
HPV- cancers. 
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Figure 4.6. Proposed mechanism for peritumoral neurogenesis and signaling via 
the neurotrophin receptor pathway.  
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4.4 DISCUSSION 
The proximity of tumorigenic cells to nerves is universally associated with 
poor prognosis in head and neck cancers (Tse 2012).  Neurotrophism-associated 
genes (such as NGF, BDNF, etc.) have been demonstrated to play a key role in 
neurogenic drive in the peripheral nervous system (PNS) (Kolokythas et al. 
2010). In addition, it has been previously posited that HPV transformed HNC 
carry a proclivity toward neuroendocrine differentiation in a subset of patients 
(Kraft et al. 2012).  However, the involvement of the PNS in tumorigenesis and 
metastasis remains a novel area of investigation. Ruzevick et al. recently 
demonstrated increased brain metastasis in HPV-positive head and neck 
cancers where the major anatomic site was the base of tongue (2013).  The 
tongue is highly innervated by the branches of the trigeminal, facial, 
glossopharyngeal, and vagus and has recently been demonstrated to be the 
most prevalent anatomic site in perineural invasion (this Thesis; Tai et al. 2012).  
Our data suggest that the virally-induced homeobox transcription factor POU4F1 
plays a role downstream of HPV-infection in inducing p75NTR expression as well 
as other critical neurotrophism-related genes.  Additionally, our data present the 
first mechanistic insight into the importance of p75NTR signaling in HPV-active 
versus HPV-negative.  Interestingly, our data not only clearly support a role for 
NGF but also implicate downstream GABA and Glutamate signaling within the 
periphery.  GAD1, the key synthetic enzyme that converts glutamate to GABA, 
has recently been shown to promote invasion and metastasis in oral cancers 
(Kimura et al. 2013).  Furthermore, activity of glutamate receptor ionotrophic 2C 
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(GRIN2C), glutamate receptor metabotrophic 8 (GRM8), and various aspects of 
the glutamate signaling cascade provide intriguing targets for further 
investigation.  The glutamatergic system has been implicated in GWAS studies 
by Vink et al. including these aforementioned targets which are increased in 
smokers versus non-smokers (Vink et al. 2009). It is well accepted that cancer 
patients on β-adrenergic blockers have lower rates of recurrence and diminished 
mortality (Barron et al. 2011; Melhem-Bertrandt et al. 2011; Lemeshow et al. 
2011; Grytli et al. 2013; Grytli et al. 2013).  Recent mechanistic evidence in 
prostate cancer suggests a dualism between the sympathetic and 
parasympathetic disease (Magnon et al. 2013).  Neurotrophins are expressed in 
abundance in saliva and play pleiotrophic roles in maintaining the 
sympathetic/parasympathetic tempo within the upper aerodigestive tract (Laurent 
et al. 2013).  Interestingly, acetylation of the H3 in proximity to POU4F1 has been 
suggested as a mechanism of control in regulating sensory ganglia development 
(Eng et al. 2007). 
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CHAPTER 5 
FUTURE DIRECTIONS AND TRANSLATIONAL PERSPECTIVES 
 
Taken together and in light of our big data observations in patients with 
HNC we suggest a critical role for the involvement of the nervous system in 
neoplasia of the head and neck.  Despite inclusion of HPV screening in the 
pathological work-up of all patients, HNC remains a disease intricately 
associated with neurostress-related behaviors and outcomes.   
Our data collectively suggest an increased role of the peripheral nervous 
system in HNC including how it might relate to relevant clinical subtypes (e.g., 
HPV+, HPV-).  Centering around the nerve growth factor receptor (NGFR) and 
associated downstream targets, we suggest potential molecular targets for future 
therapeutic development including the NGFR/ NFκβ /ERK pathway.  Based on 
the finding that p75NTR levels were significantly up-regulated in HPV+ vs. HPV- 
HNC a more complete analysis of the functionality of the p75NTR/TrkB receptors 
in virally driven versus non-virally driven HNC cells is warranted.  NGFR has 
previously been shown to be increased in HNC but not in the context of HPV 
infection (Søland et al. 2008).  Because p75NTR has previously been suggested 
to play a growth suppressive role in maintaining the bOK niche, we hypothesize 
that HPV-mediated trans-differentiation might result in aberrant NGFR signaling.  
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ProNGF induces a pro-apoptotic and growth suppressive signal via NFκβ 
(Rabizadeh S et al. 1993).  ProNGF treatment substantially reduces cell viability 
and induces increased TUNEL and cleaved caspase-3 activity, indicative of 
apoptosis.  BDNF treatment results in a similar effect.  Because the BDNF 
promoter was recently demonstrated to be hypermethylated in HPV-driven HNC 
(Kostareli et al. 2013) and because we demonstrated changes in NGFR, a 
common cognate receptor to the TrkB BDNF promoter, GDNF regulation of the 
basal compartment in HPV infected cells might promote aberrant neurogenesis.   
The preponderance of neural crest-related genes suggest another 
intriguing target.  To determine critical neural gene expression targets, we 
conducted a full deep learning analysis of our dataset and discovered several 
important neural crest transcription factors.  POU4F1 is an essential transcription 
factor best known for the role it takes in regulating neurogenesis and neural 
development in concert with various factors (Islet 1,ISL1; LIM-Homeobox 1, 
LHX1; Paired-box Homeobox 1, PAX1) within the sensory ganglia and 
throughout the craniofacial axis (Eng et al. 2007).  POU4F1 is also implicated as 
an HPV-induced transcription factor in cervical cancer and has been shown to be 
increased in response to HPV16 infection (Ndisang et al. 2001; Ndisang D et al. 
2006).  The presence of POU4F1 and other neurogenic factors might lead us to 
consider the involvement of POU4F1 and it’s principal binding partner ISL1 in 
HPV16-positive and HPV16-negative cell lines and downstream druggable 
targets in HNC. POU4F1 and ISL1 were up-regulated in HPV+ versus HPV- HNC 
suggesting involvement of this highly conserved transcriptional program.   
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Finally, with pain as a sentinel symptom of many HPV-driven HNC cases 
(McIlwain et al. 2014), we discovered several pain-associated receptors including 
TRPV6, GRIN2C as well as involvement of GABRP and GAD suggesting an 
important role of the nervous system.  Expanding upon these machine-learning 
findings with pathologist-confirmed PNI cases might present additional 
translational targets or validate known interventions, such as surgical or chemical 
denervation strategies, in HNC. 
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APPENDIX A 
TCGA MACHINE LEARNING QUALITY CONTROL 
   
 
 
 
 
 
 
Figure A.1. Comparison of DeSeq2 and Edge R log FC versus mean normalized 
counts, demonstrating high concordance between methods and 83 overlapping 
neurogenesis genes in the PNI+ dataset (B). 
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APPENDIX B 
MASSIVELY PARALLEL SEQUENCING PARAMETERS 
 
 
